Invizius's Pioneering Dialysis Product H-Guard® Completes First In-Human Clinical Study

Study demonstrated safety and tolerability of H-Guard®, a second generation complement regulator, designed to address serious immune system-driven complications of dialysis.Encouraging biomarker data positions H-Guard for upcoming Acute Kidney Injury (AKI) trial focused on reducing complement mediated renal tubu...

Related Keywords

United Kingdom ,Stockholm ,Sweden ,Manchester ,Sandip Mitra ,Duha Ilyas ,Ilyas Duha ,Magnus Nicolson ,Leonard Ebah ,Professor Of Renal Medicine At Manchester University ,Care Research ,Manchester Clinical Research Facility ,National Institute For Health ,Invizius Limited ,Manchester University ,Acute Kidney Injury ,Continuous Renal Replacement Therapy ,National Institute ,Priming Solution ,Manchester Royal Infirmary ,Professor Sandip Mitra ,Intensive Care Unit ,Chronic Kidney Disease ,Chief Executive Officer ,Professor Mitra ,Consultant Nephrologist ,Renal Medicine ,Stockholm May ,